BioPharma Resources

Drug Trial Radar · NCT07447986

To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SG301 SC Injection in Patients With Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Mar 26, 2026

Primary completion

Sep 30, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study. The primary objective was to evaluate the efficacy of SG301 SC injection in participants with Systemic Lupus Erythematosus (SLE) based on the Systemic Lupus Erythematosus Responder Index -4 (SRI-4) response rate. The secondary objectives were to assess the safety, pharmacokinetics, pharmacodynamics, and immunogenicity profiles of SG301 SC injection in these participants .

Conditions

  • Systemic Lupus Erythematosus (SLE)

Interventions

  • SG301 SC InjectionDrug

    One injection per week for 8 doses, followed by one injection every two weeks for another 8 doses, with a total of 16 injections administered.

  • SG301 SC InjectionDrug

    One injection per week for 8 doses, followed by one injection every two weeks for another 8 doses, with a total of 16 injections administered, among which 2 injections are placebos

  • SG301 SC placeboDrug

    One injection per week for 8 doses, followed by one injection every two weeks for another 8 doses, with a total of 16 injections administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4)Time frame: From baseline to week 25

Locations

40 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • Xiamen Hospital of Traditional Chinese Medicine

    Xiamen, Fujian, China · Recruiting

  • Xiamen University Affiliated Zhongshan Hospital

    Xiamen, Fujian, China · Recruiting

  • GanSu Provincial Hospital

    Lanzhou, Gansu, China · Recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Recruiting

  • ZhuJiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Guilin Medical University

    Guilin, Guangxi, China · Recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Recruiting

  • Hebei Zhongyuan Petrolium Central Hospital

    Langfang, Hebei, China · Recruiting

  • Hebei General Hospital

    Shijiazhuang, Hebei, China · Recruiting

  • The 2nd Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Not yet recruiting

  • Luoyang Central Hospital

    Luoyang, Henan, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Recruiting

  • Pingxiang People's Hospital

    Pingxiang, Henan, China · Recruiting

  • People's Hospital of Zhengzhou

    Zhengzhou, Henan, China · Recruiting

  • JingZhou Central Hospital

    Jingzhou, Hubei, China · Recruiting

  • Shiyan People's Hospital

    Shiyan, Hubei, China · Recruiting

  • The Central Hospital of Wuhan

    Wuhan, Hubei, China · Recruiting

  • Yichang Central People's Hospital

    Yichang, Hubei, China · Recruiting

  • Zhuzhou Central Hospital

    Zhuzhou, Hunan, China · Recruiting

  • Changzhou Second People's Hospital

    Changzhou, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Recruiting

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China · Recruiting

  • Yichun People's Hospital

    Yichun, Jiangxi, China · Recruiting

  • Jilin Provincial People's Hospital

    Changchun, Jilin, China · Recruiting

  • Jilin University First Hospital

    Changchun, Jilin, China · Recruiting

  • Dalian Municipal Central Hospital

    Dalian, Liaoning, China · Recruiting

  • Jining First People's Hospital

    Jining, Shandong, China · Recruiting

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, China · Recruiting

  • The First Affiliated Hospital of Gannan Medical University

    Ganzhou, Shanxi, China · Recruiting

  • Linfen Central Hospital

    Linfen, Shanxi, China · Recruiting

  • Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Recruiting

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China · Recruiting

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First People's Hospital of Yunnan Prevince

    Kunming, Yunnan, China · Recruiting

  • Huzhou Third People's Hospital

    Huzhou, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.